NEW YORK, Oct. 27 The Financial Times announces the launch of its special report 'Combating AIDS.' The supplement will be distributed in all global editions of the FT on Tuesday 1st December 2009, to coincide with World AIDS Day.
Following the success of the FT special report on 'Combating Malaria,' published in April 2009, 'Combating AIDS' is the second in a series of FT reports on major diseases. 'Combating Tuberculosis' and a second installation of 'Combating Malaria,' will be published to coincide with international fundraising campaigns and awareness days in 2010.
'Combating AIDS' will include the following features:
The FT will donate a portion of the proceeds from this special report to the Global Business Coalition (GBC) to fund the NGO's efforts to fight HIV/AIDS, tuberculosis and malaria.
"The Financial Times realizes the vital need to devote its global scope and editorial insight to better understanding and combating the AIDS epidemic," said Andrew Sollinger, Managing Director of the FT's US Commercial Operations. "We are pleased to combine these efforts with the Global Business Coalition, an organization that effectively brings together leaders in the public and private sectors to improve public health."
"The fight against HIV/AIDS cannot be won without the corporate sector stepping up and playing an active role. This is a business story, and it's fitting that a business newspaper read by high-level corporate leaders is making this part of its editorial agenda," said John Tedstrom, President and CEO of the Global Business Coalition. "We're pleased that FT has once again demonstrated its commitment to keeping AIDS, and its impact on public health and economic development, a top-line issue for the corporate community. It's a major asset in our global fight."
For information on advertising opportunities, please contact Beverly Fontanella in the US at +1 212-641-6429 or firstname.lastname@example.org or Julia Woolley in the UK at +44 (0) 1473 652964 or julia.woolley@FT.com. Please note the deadline for reserving advertising space is November 10.
For more information on this and other Financial Times special reports, go to www.ft.com/reports.
About the Financial Times:
The Financial Times, one of the world's leading business news organisations, is recognised internationally for its authority, integrity and accuracy. Providing extensive news, comment and analysis, the newspaper is printed at 23 print sites across the globe, has a daily circulation of 408,544 (ABC figures, September 2009) and a readership of 1.3 million people worldwide. FT.com is the definitive home for business intelligence on the web, providing an essential source of news, comment, data and analysis for the global business community. FT.com attracts 11.4 million unique users, generating 83.2 million page views (ABCe figures, March 2009) and now has over 1.6 million registered users.
About Global Business Coalition on HIV/AIDS, TB and Malaria:
The Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria is a coalition of more than 220 companies united to keep the fight against these epidemics a global priority. The Coalition provides tailored support so that companies can take an active role in defeating the pandemics. The Coalition also organizes collective actions among companies and links the public and private sectors in ways that pool talents and resources. The official focal point of the private sector delegation to the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Coalition maintains offices in New York, Paris, Johannesburg, Beijing, Nairobi and Moscow. For more information visit: http://www.gbcimpact.org.
-- A look at the principal causes and transmission routes of the disease -- An analysis of the pandemic's impact on individuals and societies worldwide -- An exploration of how corporations have responded to the AIDS crisis, including specific case studies -- A look at the role education, awareness and advocacy programs will continue to play in shaping effective anti-AIDS initiatives -- A examination of the scientific and pharmaceutical responses to AIDS, including a look at the latest developments in vaccines, drugs and diagnostic processes
SOURCE Financial Times